Hellenic Society for Social Pediatrics and Health Promotion, Athens, Greece; Department of Pediatric Hematology-Oncology, "P&A Kyriakou" Children's Hospital, Athens, Greece.
Hellenic Society for Social Pediatrics and Health Promotion, Athens, Greece; Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece.
Cancer Epidemiol. 2022 Jun;78:102153. doi: 10.1016/j.canep.2022.102153. Epub 2022 Apr 4.
We used, for the first time, data registered in the Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST)-Greece to estimate incidence/time trends of the rare childhood (0-14 years) non-Wilms tumors (non-WT), and compared the results of malignant non-WT to those from the Surveillance, Epidemiology, and End Results Program (SEER)-USA.
Fifty-five cases (n = 33 malignant-only) were extracted from NARECHEM-ST (2001-2020) and 332 malignant cases from SEER (1990-2017). To allow between-country comparisons, age-standardized incidence rates (AIR) of malignant-only non-WT were calculated, and temporal trends were evaluated using Poisson and joinpoint regressions.
In NARECHEM-ST, malignant and non-malignant non-WT accounted for 22.6% of all renal tumors. Among malignant tumors, the AIR was 1.0/10 children in Greece, similar to that calculated for SEER, USA (AIR=0.9/10). The proportion of infant malignant and non-malignant non-WT was 27% (20% before 6 months) in NARECHEM-ST. Most common non-WT in Greece were congenital mesoblastic nephromas (CMN) diagnosed mainly in infancy (CIR=7.2/10). The proportion of infant malignant non-WT was 20% in SEER (AIR=2.5/10), mainly attributed to rhabdoid tumors (CIR=1.6/10). The male-to-female (M:F) ratio of malignant non-WT was 0.9 in NARECHEM-ST vs. 1.2 in SEER, whereas boys outnumbered girls with clear cell sarcoma in NARECHEM-ST (M:F=4.0). Lastly, significantly increasing trends in incidence rates were noted in NARECHEM-ST [+ 6.8%, 95% confidence intervals (CI): 0.5, 13.3] and in SEER (+7.3%, 95%CI: 5.6, 9.0).
Observed incidence, time trends and sociodemographic variations of non-WT may reflect differential registration practices and healthcare delivery patterns including differences regarding surveillance, coding and treatment practices.
我们首次使用全国儿童血液系统恶性肿瘤和实体瘤登记处（NARECHEM-ST）-希腊登记的数据来估计罕见的儿童（0-14 岁）非 Wilms 肿瘤（非 WT）的发病率/时间趋势，并将恶性非 WT 的结果与美国监测、流行病学和最终结果计划（SEER）的结果进行比较。
从 NARECHEM-ST（2001-2020 年）中提取了 55 例（n=33 例恶性肿瘤）和 SEER（1990-2017 年）中 332 例恶性病例。为了进行国家间比较，计算了仅恶性非 WT 的年龄标准化发病率（AIR），并使用泊松和联合点回归评估了时间趋势。
在 NARECHEM-ST 中，恶性和非恶性非 WT 占所有肾肿瘤的 22.6%。在恶性肿瘤中，希腊的 AIR 为每 10 名儿童 1.0 例，与美国 SEER 计算的 AIR 相似（AIR=0.9/10）。NARECHEM-ST 中婴儿恶性和非恶性非 WT 的比例为 27%（6 个月前为 20%）。希腊最常见的非 WT 是先天性中胚层肾瘤（CMN），主要在婴儿期诊断（CIR=7.2/10）。SEER 中婴儿恶性非 WT 的比例为 20%（AIR=2.5/10），主要归因于横纹肌肉瘤（CIR=1.6/10）。NARECHEM-ST 中恶性非 WT 的男女比例为 0.9，而 SEER 中为 1.2，而透明细胞肉瘤在 NARECHEM-ST 中男孩多于女孩（M:F=4.0）。最后，NARECHEM-ST 中发病率呈显著上升趋势[+6.8%，95%置信区间（CI）：0.5，13.3]，SEER 中发病率呈上升趋势[+7.3%，95%CI：5.6，9.0]。
观察到的非 WT 的发病率、时间趋势和社会人口统计学变化可能反映了不同的登记实践和医疗保健提供模式，包括监测、编码和治疗实践方面的差异。
